eric593 wrote:This is also a drug-eluting stent so hopefully that will reduce some of the early risks we see with vein dilation or stent use in CCSVI.
It is? That's exciting! Do you know what the drug works against? Is it anti-clotting or anti-regrowth, when it's said to be anti-restenotic?
The other problem is that stents irritate the vein at both ends of the stent, so you get a "candy-wrapper" restenosis with the stent open inside the stent but the vein just past it closed on both sides. Would the drugs work against this, do you think? Even if they didn't, at least they'd work against the other types of in-stent restenosis.
And seriously - candy-wrapper stent restenosis, not to be confused with candy-wrapper twisting malformation in the azygous - do these IRs deliberately name everything the same? For how creative they are, couldn't they be just a bit more creative in the naming department?
My other concern with these resorbable stents is that we used to think of CCSVI as narrowings, which these would be perfect for. But now there's so much more known about the valves. If a stent squished a valve up against the vein for a year and a half before the stent resorbed, would the valve be defeated or would it pop back out at that time? It might still be that the better approach is to annihilate the valve in the first place.
I think it's still a fantastic advance.